Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjunctive pimavanserin for major depressive disorder with inadequate antidepressant response
2018-003251-37Phase 3Terminated
- Sponsor
- Acadia Pharmaceuticals
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Adjunctive pimavanserin with Adjunctive placebo (2 arms). Primary endpoint: Change from baseline in Hamilton Depression Scale (17 items) total score. Started Apr 2019; status: terminated.
02
Drugs
pimavanserin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-003251-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003251-37.